Search PubMed⌕ Search

Biomedical subjects

U Gundert-Remy

Publications and source records attributed to U Gundert-Remy.

30 records · Page 2Linked to original sources
PubMed1978

3H-Cymarol in man. Excretion pathways and serum protein binding.

In 10 patients, 5 having received 3H-cymarol i.v., 5 orally, the radioactivity in plasma, urine and in the feces of some patients also was determined. After oral administration the plasma levels rose rapidly reaching maximum levels 1--2 h after administration. After i.v. injection about 30% of the given radioactivity were excreted in the urine. The remaining radioactivity was found in the feces suggesting a high biliary excretion. Only 10% of the radioactivity excreted in the first 24 h were chloroform-extractable. The radioactivity found in the urine after oral administration of the drug amounted to 17.6%. Between 51.1 and 58.5% of the drug were bound to serum proteins.

Aged↗
PubMed1976

[Sitosterol in familial hyperlipoproteinemia type II. A randomized double-blind cross-over study].

The effect of beta-sitosterol on the lipid and lipoprotein level was evaluated in a randomised double-blind cross-over trial in 24 patients with primary familial type II hyperlipoproteinaemia over a period of 16 weeks. All patients completed the trial, however 10 of them had to be excluded from the evaluation due to fluctuations of their body weight or unreliable drug intake. Sitosterol lowered the total cholesterol level by 12.5% (P less than 0.01) from 9.96 mmol/l (3.69 g/l) to 8.37 mmol/l (3.23 g/l). The LDL-cholesterol level was lowered by 19.5% (P less than 0.05). The sitosterol concentration in plasma was consistently lower than 0.3% of total cholesterol. No side effects or tachyphylaxis was observed in the course of the trial. A return to normal of an increased serum cholesterol level by a combination of a lipid lowering diet and sitosterol monotherapy was only achieved in one patient.

Adolescent↗
PubMed1976

Serum digoxin levels in patients of a general practice in Germany.

Serum digoxin levels were determined in 33 outpatients of a general practice in the countryside, on three occasions at intervals of 8 weeks. All the patients were on long term digoxin treatment, about 2 years on average. About 14 days after the first and the second visits the results of the measurements were sent to the patients, with a comment about their reliability in taking treatment according to the serum digoxin level. At the first visit half of the serum digoxin level were lower than 0.5 ng/ml; the mean serum concentration was 0.52 ng/ml. There was no correlation between serum concentration and age, dose or creatinine level; but there was with replies to the question about regularity of drug intake. The mean serum level at the second and the third visits was 0.88 ng/ml and 0.89 ng/ml, respectively. A correlation was found between the dose and the serum digoxin level. From these results it seems that compliance by the patient plays a major role in producing steady state levels of drugs.

Aged↗
PubMed1975

[Biological availability].

The term "bioavailability" is used to describe the actual percentage of a drug released from the dosage form, which reaches the receptor site in sufficient quantity to induce a biological effect. In this connection there are many problems arising in conjunction with the formulation of the preparation, as well as through the interaction of physiological and pathological factors. Prerequisite to the bioavailability of an orally administered preparation is, firstly, the quick disintegration of the dosage form, and secondly, the release and dissolution of the active substance. No in vitro methods for the examination of these factors have as yet been evolved which would allow a reliable prediction of bioavailability in man. Animal experiments only permit limited prognoses, since numerous influential factors, such as absorption from the intestine, metabolism and metabolic rates, influence of physical and mental stress, etc., strongly dependent upon the species. Bioavailability is determined using pharmacokinetical techniques on the area affected by the dose-response curve, or a combination of these methods.

Administration, Oral↗